NCT06868654 - China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

April 3, 2024

Study Completion Date

June 19, 2026

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

DRUG

Daratumumab

Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody

DRUG

Bortezomib

Proteasome Inhibitor

DRUG

Dexamethasone

Synthetic glucocorticoid with anti-tumor activity

Trial Locations (11)

GSK Investigational Site, Beijing

GSK Investigational Site, Changchun

GSK Investigational Site, Guangzhou

GSK Investigational Site, Hangzhou

GSK Investigational Site, Jinan

GSK Investigational Site, Nanjing

GSK Investigational Site, Shenyang

GSK Investigational Site, Suzhou

GSK Investigational Site, Tianjin

GSK Investigational Site, Wuhan

GSK Investigational Site, Zhengzhou